Teladoc Health, Inc. - TDOC STOCK NEWS

Teladoc Health (TDOC) reported first quarter 2023 revenue of $629.2 million, reflecting an 11% year-over-year growth. However, the company posted a net loss of $69.2 million or ($0.42) per share, compared to a substantial loss of $6.67 billion in Q1 2022, which was mainly due to a prior goodwill impairment. Adjusted EBITDA decreased by 3% to $52.8 million. The Integrated Care segment saw revenue growth of 5% to $350 million, while BetterHelp revenue surged 21% to $279.3 million. Looking ahead, Teladoc projects Q2 2023 revenue of $635 - $660 million and expects a full year 2023 revenue between $2.575 - $2.675 billion. The financial outlook indicates potential improvement despite ongoing losses.

Teladoc Health is expanding its Provider-Based Care to include weight management and prediabetes programs, addressing a significant health issue in the U.S., where 42% of adults are estimated to live with obesity and 1 in 3 have prediabetes. This initiative builds on its existing diabetes and hypertension solutions, offering personalized care plans and coaching through digital tools. The new service aims to optimize medications like GLP-1 agonists and SGLT2 inhibitors, ensuring comprehensive support for individuals managing cardiometabolic health risks. Launching in Q3 2023, the expansion exemplifies Teladoc's commitment to improving health outcomes through innovative, evidence-based solutions.

PURCHASE, NY, April 12, 2023 – Teladoc Health (NYSE: TDOC), a leader in virtual care, will report its first quarter 2023 results on April 26, 2023, after market close. Following the earnings announcement, a conference call is scheduled at 4:30 p.m. E.T. for an in-depth review of the results. Participants can join by calling 1-833-470-1428 (U.S.) or accessing the webcast online. A replay of the call will be available for 90 days post-event. Teladoc Health focuses on empowering healthcare access and improving outcomes through innovative virtual care solutions, backed by over a decade of expertise and high satisfaction rankings in telehealth services.

Teladoc Health (NYSE: TDOC) announced new clinical findings demonstrating the significant impact of whole-person virtual care on chronic condition management. A peer-reviewed study revealed that individuals enrolled in multiple programs, including diabetes, hypertension, and weight management, achieved enhanced clinical outcomes. Those engaging in multiple programs saw an average A1c reduction of 0.44% and a decrease in systolic blood pressure by 6.8 mmHg. This research emphasizes the effectiveness of integrated health solutions and supports the transition from standalone programs to multi-condition management, reinforcing the value of Teladoc's services for employers and health plans.

On March 25, 2023, Teladoc Health (NYSE: TDOC) announced it is offering free, 24/7 telehealth visits for Mississippi residents affected by recent tornadoes. This service is available for those displaced or unable to access medical care, allowing them to consult licensed healthcare professionals for non-emergency conditions. The initiative reflects Teladoc's commitment to community health during disasters, providing essential care and prescription authorizations as needed. The company's ongoing response to federally declared disasters ensures uninterrupted access to healthcare for non-emergency illnesses, supporting recovery efforts in affected areas.

Teladoc Health (NYSE: TDOC), a leader in whole-person virtual care, announced that its CFO, Mala Murthy, will present at the 43rd Annual TD Cowen Health Care Conference in Boston on March 6, 2023. Investors can access a live audio webcast and replay of the presentation at the company's investor relations website.

Teladoc Health focuses on improving healthcare experiences through personalized interactions and proprietary health signals, aiming to enhance health outcomes for consumers and healthcare professionals alike.

Teladoc Health reported a strong fourth quarter in 2022, with revenue increasing by 15% year-over-year to $637.7 million and an 18% rise for the full year to $2,406.8 million. Despite this growth, the company faced a substantial net loss of $3.81 billion in Q4 and $13.66 billion for the year, primarily due to non-cash goodwill impairment charges. Adjusted EBITDA rose 22% to $94.1 million in Q4, indicating operational efficiency. Looking ahead, Teladoc projects revenue between $2.55 and $2.68 billion for 2023, with expectations of reducing net losses per share significantly.

Teladoc Health, Inc. (NYSE: TDOC) will release its fourth quarter 2022 results on February 22, 2023, after market close. The company plans to host a conference call at 4:30 p.m. E.T. to discuss the results. U.S. participants can access the call at 1-844-200-6205, while international participants can dial 1-929-526-1599 using access code # 033061. A live audio webcast will also be available online. A replay will be accessible shortly after the call and will remain available for approximately 90 days. Teladoc is a leader in whole-person virtual care, providing transformative healthcare experiences to improve health outcomes.

Teladoc Health has published its third annual corporate social responsibility report, showcasing a commitment to health equity and community well-being. Highlights include a 33% increase in employee volunteerism, financial aid of $18 million for low-income therapy costs, and the deployment of 18 telehealth devices to Ukraine. The report signifies a landmark year for the company, marking its 50 millionth visit and 20th anniversary in 2022. CEO Jason Gorevic emphasizes the mission to empower healthier communities through equitable quality care. The full report is available online.